These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex. Wang W; Guo H; Shi B; Sun H; Li H; Zhang Y; Cai Y Int Urol Nephrol; 2019 Apr; 51(4):671-676. PubMed ID: 30756282 [TBL] [Abstract][Full Text] [Related]
4. Role of mTOR inhibition in the treatment of patients with renal angiomyolipomas. Coombs EJ J Am Assoc Nurse Pract; 2013 Nov; 25(11):588-96. PubMed ID: 24170533 [TBL] [Abstract][Full Text] [Related]
5. Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex. Peces R; Peces C; Cuesta-López E; Pérez-Dueñas V; Vega-Cabrera C; Azorín S; Selgas R Nephrol Dial Transplant; 2010 Nov; 25(11):3787-91. PubMed ID: 20663789 [TBL] [Abstract][Full Text] [Related]
6. Percutaneous cryoablation for tuberous sclerosis-associated renal angiomyolipoma with neoadjuvant mTOR inhibition. Krummel T; Garnon J; Lang H; Gangi A; Hannedouche T BMC Urol; 2014 Sep; 14():77. PubMed ID: 25258166 [TBL] [Abstract][Full Text] [Related]
7. Review of the Tuberous Sclerosis Renal Guidelines from the 2012 Consensus Conference: Current Data and Future Study. Kingswood JC; Bissler JJ; Budde K; Hulbert J; Guay-Woodford L; Sampson JR; Sauter M; Cox J; Patel U; Elmslie F; Anderson C; Zonnenberg BA Nephron; 2016; 134(2):51-58. PubMed ID: 27504842 [TBL] [Abstract][Full Text] [Related]
8. Microscopic Kidney Disease in Tuberous Sclerosis Complex and Treatment With mTOR Inhibition. Kronick J; Gabril MY; House AA Am J Kidney Dis; 2023 Dec; 82(6):772-775. PubMed ID: 37532078 [TBL] [Abstract][Full Text] [Related]
9. Patterns of Disease Monitoring and Treatment Among Patients With Tuberous Sclerosis Complex-related Angiomyolipomas. Swallow E; King S; Song J; Peeples M; Signorovitch JE; Liu Z; Prestifilippo J; Frost M; Kohrman M; Korf B; Krueger D; Sparagana S Urology; 2017 Jun; 104():110-114. PubMed ID: 28263820 [TBL] [Abstract][Full Text] [Related]
11. Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients. Brakemeier S; Bachmann F; Budde K Pediatr Nephrol; 2017 Jul; 32(7):1137-1144. PubMed ID: 27585680 [TBL] [Abstract][Full Text] [Related]
12. The efficacy of cannabidiol on renal angiomyolipoma and subependymal giant cell tumor volume in tuberous sclerosis complex. Barnett JR; Grinspoon RA; Harisinghani M; Caruso PA; Thiele EA J Clin Neurosci; 2020 Jul; 77():85-88. PubMed ID: 32409220 [TBL] [Abstract][Full Text] [Related]
13. Regression of renal angiomyolipomas with oral rapamycin therapy in a patient with tuberous sclerosis complex disease. Torun D; Micozkadioglu H; Gedikoglu M; Ozelsancak R; Tekkarismaz N Saudi J Kidney Dis Transpl; 2019; 30(2):545-548. PubMed ID: 31031395 [TBL] [Abstract][Full Text] [Related]
14. Possible prevention of tuberous sclerosis complex lesions. Kotulska K; Borkowska J; Jozwiak S Pediatrics; 2013 Jul; 132(1):e239-42. PubMed ID: 23733802 [TBL] [Abstract][Full Text] [Related]
15. Sporadic versus Tuberous Sclerosis Complex-Associated Angiomyolipomas: Predictors for Long-Term Outcomes following Transcatheter Embolization. Sheth RA; Feldman AS; Paul E; Thiele EA; Walker TG J Vasc Interv Radiol; 2016 Oct; 27(10):1542-9. PubMed ID: 27522275 [TBL] [Abstract][Full Text] [Related]
16. Renal angiomyolipoma with tuberous sclerosis complex: How it differs from sporadic angiomyolipoma in both management and care. Hatano T; Egawa S Asian J Surg; 2020 Oct; 43(10):967-972. PubMed ID: 31959574 [TBL] [Abstract][Full Text] [Related]
17. The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions. Curatolo P; Bjørnvold M; Dill PE; Ferreira JC; Feucht M; Hertzberg C; Jansen A; Jóźwiak S; Kingswood JC; Kotulska K; Macaya A; Moavero R; Nabbout R; Zonnenberg BA Drugs; 2016 Apr; 76(5):551-65. PubMed ID: 26927950 [TBL] [Abstract][Full Text] [Related]
18. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex. MacKeigan JP; Krueger DA Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591 [TBL] [Abstract][Full Text] [Related]
19. Effect of everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex: an evaluation based on tumor density. Hatano T; Atsuta M; Inaba H; Endo K; Egawa S Int J Clin Oncol; 2018 Jun; 23(3):547-552. PubMed ID: 29256023 [TBL] [Abstract][Full Text] [Related]
20. Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial. Cai Y; Guo H; Wang W; Li H; Sun H; Shi B; Zhang Y Orphanet J Rare Dis; 2018 Mar; 13(1):43. PubMed ID: 29587809 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]